Background: This study aimed to evaluate the efficiency of immunostaining with p16 and Ki-67 in cervical cytology specimens for the detection of cervical intraepithelial neoplasia (CIN) in a high risk population.Methods: This was a prospective review of 287 women who underwent pap smear, human papilloma virus (HPV) testing and colposcopy examination, respectively. There were cervical smear abnormalities in 108 women (37.6%) and 141 patients (49.1%) tested positive for HPV. Cervical biopsy revealed normal cervix in 28 patients (9.75%), cervicitis in 48 patients (16.72%), CIN1 in 178 patients (62.02%), CIN2 in 26 patients (9.05%) and CIN3 in 7 patients (2.43%).Results: Positive staining for p16 had a sensitivity of 78.2% and a specificity of 97.4% while positive staining for Ki67 had a sensitivity of 80.6% and a specificity of 57.9% for distinguishing CIN lesions in cervical cytology specimens (p=0.001 for both). Concurrent positive staining for p16 and Ki67 in cervical cytology specimens had a sensitivity of 80.6% and a specificity of 97.4% for CIN lesions (p=0.001). Positive staining for p16 had a sensitivity of 94% and a specificity of 90.6% whereas positive staining for Ki67 had a sensitivity of 97% and a specificity of 33% for differentiating CIN lesions in colposcopic biopsy specimens (p=0.001 for both). Concurrent positive staining for p16 and Ki67 in colposcopic biopsy specimens had a sensitivity of 91% and a specificity of 94% for CIN lesions (p=0.001).Conclusions: p16/Ki-67 immunostaining applied on cervical cytology specimens can screen CIN lesions with high sensitivity and specificity in a low risk population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.